Press release
Mantle Cell Lymphoma Pipeline Analysis: Emerging Therapies, Market Trends, and Next-Generation Treatment Innovations Transforming the Mantle Cell Lymphoma Drug Market | DelveInsight
Key Takeaways from the Mantle Cell Lymphoma Pipeline and Treatment Landscape Report
• DelveInsight's Mantle Cell Lymphoma pipeline analysis highlights a dynamic therapeutic landscape with multiple companies advancing innovative targeted therapies, CAR-T cell therapies, bispecific antibodies, and next-generation immuno-oncology treatments.
• Key Mantle Cell Lymphoma companies such as Roche, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, PharmaEngine, and others are actively contributing to pipeline growth.
• Promising Mantle Cell Lymphoma pipeline therapies include Glofitamab, LP-168, GLPG5101, Zamtocabtagene autoleucel, PEP07, and others.
• The growing adoption of targeted therapies and cellular immunotherapies is significantly transforming the Mantle Cell Lymphoma treatment market.
• Advancements in BTK inhibitors, CAR-T therapies, and CD20xCD3 T-cell-engaging antibodies continue to expand opportunities across the Mantle Cell Lymphoma drug market and industry.
Request a sample and discover the latest advancements in Mantle Cell Lymphoma treatment drugs, emerging therapies, market size, market share, and pipeline developments. Mantle Cell Lymphoma
What is Mantle Cell Lymphoma?
Mantle Cell Lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin lymphoma that originates from B lymphocytes within the mantle zone of lymph nodes. The disease accounts for approximately 5-7% of all non-Hodgkin lymphoma cases and primarily affects older adults between 60 and 70 years of age. MCL is characterized by cyclin D1 overexpression resulting from the t(11;14)(q13;q32) chromosomal translocation, which drives malignant cell proliferation. Despite initial responsiveness to treatment, relapse remains common, creating a significant unmet need within the Mantle Cell Lymphoma treatment market.
The disease is more prevalent in men and remains one of the most clinically challenging B-cell malignancies due to its aggressive nature and recurrent disease course. Increasing research efforts and advancements in precision medicine are expected to reshape the future of the Mantle Cell Lymphoma market and treatment landscape.
Emerging Mantle Cell Lymphoma Drug Profiles
LP-168: Jiangsu Hansoh Pharmaceutical
LP-168 is an oral, next-generation Bruton's tyrosine kinase (BTK) inhibitor being developed for the treatment of Mantle Cell Lymphoma. The therapy is designed to inhibit BTK signaling pathways that play a critical role in B-cell survival and proliferation. Early clinical studies have demonstrated encouraging efficacy, particularly among relapsed or refractory patients who have limited treatment options. Currently, LP-168 is being evaluated in Phase II clinical development for Mantle Cell Lymphoma.
Glofitamab: Roche
Glofitamab is a CD20xCD3 T-cell-engaging bispecific antibody designed to redirect T-cells toward malignant B-cells, promoting targeted tumor cell destruction. The therapy has emerged as one of the most promising late-stage candidates and is currently being evaluated in Phase III clinical development for Mantle Cell Lymphoma.
GLPG5101: Galapagos NV
GLPG5101 is an investigational CD19-directed CAR-T cell therapy being developed for relapsed or refractory B-cell malignancies, including Mantle Cell Lymphoma. The therapy is currently in Phase II development and reflects the growing importance of cellular therapies within the Mantle Cell Lymphoma treatment market.
Zamtocabtagene Autoleucel: Miltenyi Biomedicine
Zamtocabtagene autoleucel is an advanced CAR-T cell therapy under Phase II clinical development. The therapy is being investigated for its potential to deliver durable responses and address unmet needs among patients with relapsed or refractory Mantle Cell Lymphoma.
PEP07: PharmaEngine
PEP07 is an emerging early-stage therapy currently progressing through Phase I clinical development. The candidate highlights the industry's continued investment in developing innovative treatment approaches for patients with difficult-to-treat Mantle Cell Lymphoma.
Learn more about the novel and emerging Mantle Cell Lymphoma pipeline therapies driving innovation across the Mantle Cell Lymphoma treatment market and drug industry. Mantle Cell Lymphoma
Recent Developments in the Mantle Cell Lymphoma Clinical Trial Landscape
• In November 2025, BeOne Medicines announced that the US FDA accepted and granted Priority Review to a New Drug Application for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma following BTK inhibitor therapy.
• In December 2024, Galapagos NV reported additional data from its ongoing Phase I/II ATALANTA-1 study evaluating GLPG5101, demonstrating encouraging efficacy and safety outcomes in relapsed or refractory non-Hodgkin lymphoma patients.
• In August 2024, Hansoh Pharmaceutical and Lupeng Pharma entered into a licensing agreement related to LP-168, strengthening development and commercialization opportunities for the BTK inhibitor.
• Increasing investment activity, strategic collaborations, and regulatory support continue to accelerate innovation within the Mantle Cell Lymphoma pipeline landscape.
Scope of the Mantle Cell Lymphoma Pipeline Report
• Coverage: Global
• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, Mono/Combination
• Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase I/II, Phase II, Phase III
• Therapeutic Assessment by Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, and Others
• Therapeutic Assessment by Molecule Type: Small Molecules, CAR-T Cell Therapies, Bispecific Antibodies, Monoclonal Antibodies, Cell Therapies, and Other Emerging Modalities
• Key Mantle Cell Lymphoma Companies: Roche, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, PharmaEngine, and others.
• Key Mantle Cell Lymphoma Pipeline Therapies: Glofitamab, LP-168, GLPG5101, Zamtocabtagene autoleucel, PEP07, and others.
Dive deep into rich insights for new Mantle Cell Lymphoma treatment drugs, clinical trial developments, market size, market share, competitive intelligence, and future forecasts. Mantle Cell Lymphoma
Table of Contents
• Mantle Cell Lymphoma Pipeline Report Introduction
• Mantle Cell Lymphoma Pipeline Executive Summary
• Mantle Cell Lymphoma Disease Overview
• Causes and Risk Factors
• Pathophysiology
• Diagnosis and Treatment Landscape
• Mantle Cell Lymphoma Pipeline Therapeutics
• Late-Stage Products (Phase III)
• Mid-Stage Products (Phase II)
• Early-Stage Products (Phase I/II)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products
• Therapeutic Assessment
• Product Type Assessment
• Route of Administration Assessment
• Molecule Type Assessment
• Inactive Products Analysis
• Licensing, Partnering, and Funding Analysis
• Unmet Needs
• Market Drivers and Barriers
• Future Perspectives and Conclusion
• Appendix
• About DelveInsight
For further information on the Mantle Cell Lymphoma pipeline therapeutics, emerging treatment landscape, market trends, market share analysis, and future commercial opportunities, reach out today. Mantle Cell Lymphoma
Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mantle Cell Lymphoma Pipeline Analysis: Emerging Therapies, Market Trends, and Next-Generation Treatment Innovations Transforming the Mantle Cell Lymphoma Drug Market | DelveInsight here
News-ID: 4579371 • Views: …
More Releases from DelveInsight Business Research LLP
Celiac Disease Pipeline Analysis: Emerging Therapies, Market Trends, and Next-Ge …
DelveInsight's Celiac Disease Pipeline Insight 2026 report provides comprehensive global coverage of marketed and pipeline therapies for Celiac Disease across various stages of clinical development. The report delivers in-depth insights into the evolving Celiac Disease treatment landscape, emerging therapies, pipeline innovations, market trends, competitive intelligence, and future growth opportunities shaping the Celiac Disease market, treatment market, and autoimmune disease industry.
Key Takeaways from the Celiac Disease Pipeline and Treatment Landscape Report
• DelveInsight's…
Chondrosarcoma Pipeline, Treatment Market, and Emerging Drug Landscape Analysis: …
DelveInsight's Chondrosarcoma Pipeline Insight 2026 report provides comprehensive global coverage of marketed and pipeline therapies for Chondrosarcoma across various stages of clinical development. The report delivers in-depth insights into the evolving Chondrosarcoma treatment landscape, emerging therapies, pipeline innovations, market trends, competitive intelligence, and future growth opportunities shaping the Chondrosarcoma market and bone cancer therapeutics industry.
Key Takeaways from the Chondrosarcoma Pipeline and Treatment Landscape Report
• DelveInsight's Chondrosarcoma pipeline analysis highlights a growing…
Malignant Ascites Pipeline Accelerates as 3+ Pharma Companies Rigorously Develop …
DelveInsight's, "Malignant Ascites Pipeline Insights 2026" Report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the Malignant Ascites pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Malignant Ascites pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dive into DelveInsight's comprehensive report today!…
Polycythemia Vera Market Size in the 7MM was ~USD 2,000 Million in 2025 and It i …
DelveInsight's "Polycythemia Vera (PV) Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of Polycythemia Vera, historical and forecasted epidemiology, as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Discover Key Insights into the Polycythemia Vera Market with DelveInsight's In-Depth Report @ Polycythemia Vera Market Size-
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr
Key Takeaways from the Polycythemia Vera Market Report
•…
More Releases for Cell
Cell Sorting Market Accelerates as Cell Therapy, Immuno-Oncology & Single-Cell R …
The rising focus on precision medicine, immunotherapy, and advanced cell-based research is driving the global cell sorting market into a high-growth phase. With expanding applications in stem cell therapy, CAR-T manufacturing, cancer immunology, and single-cell genomics, demand for accurate, high-purity cell isolation systems is stronger than ever. This release highlights key market trends, segmentation insights, technological innovations, and the factors shaping the future of cell sorting.
Download Full PDF Sample Copy…
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
